Abstract:827 Introduction: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a critical pro-apoptotic molecule on the cell surface, has been identified as a promising anti-cancer agent. However, most human pancreatic cancer cells are resistant to TRAIL-induced apoptosis. This study is focused on revealing the underlying mechanisms by which pancreatic cancer cells utilize their extracellular molecules to counteract the pro-apoptotic signaling mediated by the TNF family. Methods: The binding of DcR3 (Decoy Receptor 3) with TRAIL was determined with several assays including Flow cytometry analysis, Western blotting and ELISA-like binding assay using recombinant DcR3 and TRAIL. The binding assays were also performed in both culture media and cell lysate from AsPC-1 and MiaPaCa-2 human pancreatic cancer cells. The biological function of this binding was studied with several indices for apoptosis including sub-G1 population, caspase 3 activity and cleaved PARP. Gemcitabine and siRNA for DcR3 were used to regulate the expression levels of DcR3 and TRAIL to confirm the function of the interaction of these two molecules. Results: In this study, we demonstrate for the first time that DcR3, a secreted decoy receptor expressed at a high level by malignant pancreatic cancer cells, acts as an extracellular anti-apoptotic molecule by binding to TRAIL, thus counteracting the death-promoting function of TRAIL. The reduction of DcR3 with siRNA unmasks TRAIL and greatly enhances TRAIL-induced apoptosis. Gemcitabine, a first line drug for pancreatic cancer, also reduces the level of DcR3. The addition of DcR3 siRNA could further enhance the apoptosis induced by Gemcitabine. Importantly, the in vivo studies demonstrate that the therapeutic effect of Gemcitabine is enhanced via further reduction of DcR3, suggesting that down-regulation of DcR3 in tumor cells could tip the balance from survival to death and serve as a new strategy for pancreatic cancer therapy. Conclusion: DcR3 is utilized by cancer cells for their survival upon the various stresses, including chemotherapy. The binding of DcR3 to TRAIL blocks the apoptosis induced by TRAIL. The down-regulation of DcR3 is a new strategy for enhancement of anti-cancer therapy.

Regulation of Pancreatic Cancer TRAIL Resistance by Protein O-GlcNAcylation

Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms.

The Potential Molecular Mechanism of Overexpression of Upa, IL-8, MMP-7 and MMP-9 Induced by TRAIL in Pancreatic Cancer Cell.

Regulation of cancer metabolism by O-GlcNAcylation

O-GlcNAcylation Promotes Pancreatic Tumor Growth by Regulating Malate Dehydrogenase 1

Transcriptional Regulation of O-GlcNAc Homeostasis is Disrupted in Pancreatic Cancer

Targeting O -GlcNAcylation in cancer therapeutic resistance: The sugar Saga continues

Calmodulin Antagonists Promote TRA-8 Therapy of Resistant Pancreatic Cancer.

N-Acetyl-Glucosamine Sensitizes Non-Small Cell Lung Cancer Cells to TRAIL-Induced Apoptosis by Activating Death Receptor 5

O-GlcNAcylation in cancer development and immunotherapy

The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand

OXCT1 Enhances Gemcitabine Resistance Through NF-B Pathway in Pancreatic Ductal Adenocarcinoma

Glutamine-mediated epigenetic regulation of cFLIP underlies resistance to TRAIL in pancreatic cancer

Cytoplasmic PARP‐1 Promotes Pancreatic Cancer Tumorigenesis and Resistance

O-GlcNAcylation in ovarian tumorigenesis and its therapeutic implications

Regulation of TNF-Related Apoptosis-Inducing Ligand Signaling by Glycosylation

O-GlcNAcylation of TRIM29 and OGT translation forms a feedback loop to promote adaptive response of PDAC cells to glucose deficiency

O-GlcNAcylation: an Important Post-Translational Modification and a Potential Therapeutic Target for Cancer Therapy

The roles of OGT and its mechanisms in cancer

Gemcitabine resistance induced by interaction between alternatively spliced segment of tenascin-C and annexin A2 in pancreatic cancer cells.

Down-regulation of dcr3 enhances TRAIL-mediated apoptosis in pancreatic cancer